Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.
Type:
Grant
Filed:
February 12, 2018
Date of Patent:
June 9, 2020
Assignees:
Ludwig Institute for Cancer Research Ltd., The Regents of the University of Michigan, University of Maryland, Baltimore
Inventors:
Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by employing IL-17 antagonists to a patient population defined by serum concentration of IgE and optionally also an eosinophil count in peripheral blood.
Type:
Grant
Filed:
May 3, 2018
Date of Patent:
June 9, 2020
Assignee:
NOVARTIS AG
Inventors:
Sarah Schmidt Grant, Shamsah Kazani, Edward Khokhlovich, Jason Laramie, Robert Martin Strieter, Tricia Ann Thornton-Wells
Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
Type:
Grant
Filed:
March 30, 2016
Date of Patent:
June 2, 2020
Assignee:
MEDIMMUNE LIMITED
Inventors:
Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
Type:
Grant
Filed:
June 21, 2017
Date of Patent:
May 26, 2020
Assignee:
Janssen Biotech, Inc.
Inventors:
Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Alastair King, Steven Jacobs, Shalom Goldberg, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
Abstract: A synergistic composition, kit and method for inhibition and/or neutralization of IL-21 mediated activation of human cells including (i) a first agent being an antibody or antibody fragment thereof directed to a first epitope of IL-21, and (ii) a second agent being an antibody or antibody fragment thereof directed to a second epitope of IL-21 is disclosed. The inhibition and/or neutralization of IL-21 mediated activation of human cells is for use in the prophylaxis and/or treatment of disease of immune-related conditions including inflammatory disease, autoimmunity and lymphomas.
Abstract: Methods and compositions for the use of long-acting hematopoietic factor protein analogs for accelerating hematopoietic recovery in subjects who have been or will be exposed to radiation are disclosed.
Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
May 5, 2020
Assignee:
ALDERBIO HOLDINGS LLC
Inventors:
Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
Type:
Grant
Filed:
February 26, 2019
Date of Patent:
April 28, 2020
Assignees:
MORPHOSYS AG, GALAPAGOS NV
Inventors:
Jan Dominik Haas, Jürgen Klattig, Nick Ernest Rene Vandeghinste
Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.
Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise the amino acid sequence, nucleic acids that encode the amino acid sequences, compounds or constructs, pharmaceutical compositions comprising the amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
Type:
Grant
Filed:
February 16, 2017
Date of Patent:
April 14, 2020
Assignee:
Ablynx N.V.
Inventors:
Joost Alexander Kolkman, Els Anna Alice Beirnaert
Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
Type:
Grant
Filed:
December 13, 2017
Date of Patent:
April 7, 2020
Assignee:
HANSSEN BIOTECH, INC
Inventors:
Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
Abstract: Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
April 7, 2020
Assignee:
XOMA (US) LLC
Inventors:
Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
Abstract: The present invention relates to methods for protecting against damage caused by radiation and/or chemotherapy, and methods for treating bone marrow damage by reducing/inhibiting Latexin expression and/or Latexin activity. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an antagonist that reduces expression and/or activity of latexin, wherein latexin is a latexin polynucleotide variant and/or a latexin polypeptide variant that binds to the antagonist.
Type:
Grant
Filed:
October 9, 2015
Date of Patent:
March 31, 2020
Assignee:
University of Kentucky Research Foundation
Abstract: A novel IFN-?/? independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-?1, IFN-?2, IFN-?3, based inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-? proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-?R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-?R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
March 24, 2020
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
Type:
Grant
Filed:
December 13, 2017
Date of Patent:
March 24, 2020
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
Type:
Grant
Filed:
February 23, 2016
Date of Patent:
March 17, 2020
Assignee:
The Regents of the University of California
Inventors:
Wendell A. Lim, Leonardo Morsut, Kole T. Roybal, Justin Thomas Farlow, Satoshi Toda